Please use this identifier to cite or link to this item:
DC FieldValue
dc.titleMulticentre derivation and validation of a colitis-associated colorectal cancer risk prediction web tool
dc.contributor.authorCurtius, Kit
dc.contributor.authorKabir, Misha
dc.contributor.authorAl Bakir, Ibrahim
dc.contributor.authorChoi, Chang Ho Ryan
dc.contributor.authorHartono, Juanda L.
dc.contributor.authorJohnson, Michael
dc.contributor.authorEast, James E.
dc.contributor.authorLindsay, James O.
dc.contributor.authorVega, Roser
dc.contributor.authorThomas-Gibson, Siwan
dc.contributor.authorWarusavitarne, Janindra
dc.contributor.authorWilson, Ana
dc.contributor.authorGraham, Trevor A.
dc.contributor.authorHart, Ailsa
dc.identifier.citationCurtius, Kit, Kabir, Misha, Al Bakir, Ibrahim, Choi, Chang Ho Ryan, Hartono, Juanda L., Johnson, Michael, East, James E., Lindsay, James O., Vega, Roser, Thomas-Gibson, Siwan, Warusavitarne, Janindra, Wilson, Ana, Graham, Trevor A., Hart, Ailsa (2021-05-14). Multicentre derivation and validation of a colitis-associated colorectal cancer risk prediction web tool. Gut. ScholarBank@NUS Repository.
dc.description.abstractObjective: Patients with ulcerative colitis (UC) diagnosed with low-grade dysplasia (LGD) have increased risk of developing advanced neoplasia (AN: high-grade dysplasia or colorectal cancer). We aimed to develop and validate a predictor of AN risk in patients with UC with LGD and create a visual web tool to effectively communicate the risk. Design: In our retrospective multicentre validated cohort study, adult patients with UC with an index diagnosis of LGD, identified from four UK centres between 2001 and 2019, were followed until progression to AN. In the discovery cohort (n=246), a multivariate risk prediction model was derived from clinicopathological features using Cox regression. Validation used data from three external centres (n=198). The validated model was embedded in a web tool to calculate patient-specific risk. Results: Four clinicopathological variables were significantly associated with AN progression in the discovery cohort: endoscopically visible LGD >1 cm (HR 2.7; 95% CI 1.2 to 5.9), unresectable or incomplete endoscopic resection (HR 3.4; 95% CI 1.6 to 7.4), moderate/severe histological inflammation within 5 years of LGD diagnosis (HR 3.1; 95% CI 1.5 to 6.7) and multifocality (HR 2.9; 95% CI 1.3 to 6.2). In the validation cohort, this four-variable model accurately predicted future AN cases with overall calibration Observed/Expected=1.01 (95% CI 0.64 to 1.52), and achieved 100% specificity for the lowest risk group over 13 years of available follow-up. Conclusion: Multicohort validation confirms that patients with large, unresected, multifocal LGD and recent moderate/severe inflammation are at highest risk of developing AN. Personalised risk prediction provided via the Ulcerative Colitis-Cancer Risk Estimator ( can support treatment decision-making. © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ.
dc.publisherBMJ Publishing Group
dc.rightsAttribution 4.0 International
dc.sourceScopus OA2021
dc.subjectclinical decision making
dc.subjectcolorectal cancer
dc.subjectulcerative colitis
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1136_gutjnl-2020-323546.pdf2.17 MBAdobe PDF



Google ScholarTM



This item is licensed under a Creative Commons License Creative Commons